Fibroblast Growth Factor Receptor 3 (FGFR3) Inhibitor – LY3866288
- Only pre-clinical concepts will be considered at this time
-
A Phase 1, Open-label, Multicenter Study of Vepugratinib in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations
PIRA™ suggested Proposal
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.